Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
16 juin 2022 16h00 HE
|
INVENTIVA
Update on Inventiva’s NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH and fibrosis (stage F2/F3) non-cirrhotic by Prof. Sven FrancqueUpdate on the current NASH landscape...
Inventiva annonce la présentation de trois abstracts scientifiques lors de l’EASL International Liver Congress™ 2022
09 juin 2022 16h00 HE
|
INVENTIVA
Trois présentations par poster démontrant : les effets bénéfiques de lanifibranor sur les marqueurs de la santé cardiométabolique chez les patients atteints de NASH avec fibrose non cirrhotique,...
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
09 juin 2022 16h00 HE
|
INVENTIVA
Three poster presentations showing the beneficial effects of lanifibranor on markers of cardiometabolic health in patients with non-cirrhotic NASH fibrosis independent of weight gain observed.the...
International NASH Day Highlights a Common – But Unfamiliar – Liver Disease
08 juin 2022 18h04 HE
|
Global Liver Institute
Washington, D.C., June 08, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) calls attention to NASH by leading the 5th annual International NASH Day on June 9. The number of people with this...
Inventiva publie ses informations financières du 1er trimestre 2022 et fait un point sur ses développements cliniques
16 mai 2022 16h00 HE
|
INVENTIVA
Position de trésorerie2 à €80.5 M€ au 31 mars 2022Le Groupe n’a pas généré de chiffre d’affaires au T1 2022Obtention d’un crédit « in fine » d’un montant de 50 millions d'euros de la part de la Banque...
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
16 mai 2022 16h00 HE
|
INVENTIVA
Cash position2 at €80.5m as of March 31, 2022The Group did not generate any revenue in Q1 2022Signature of a €50 million bullet credit facility agreement with the European Investment BankUpdate on...
Inventiva obtient un crédit d’un montant de 50 millions d’euros de la part de la Banque Européenne d’Investissement
16 mai 2022 02h00 HE
|
INVENTIVA
Ce financement doit permettre de soutenir la croissance et le développement du portefeuille de R&D d'InventivaLe crédit est composé de deux tranches de 25 millions d'euros chacune Cet accord...
Inventiva secures a €50 million credit facility from the European Investment Bank
16 mai 2022 02h00 HE
|
INVENTIVA
This credit facility is intended to support the progress and expansion of Inventiva’s pipelineThe credit facility consists of two tranches of €25 million eachCredit agreement is part of the European...
Growth: Global Urinalysis Market Estimated to Surpass $4,776.9 by 2028 and Grow at 6.3% CAGR in the 2021 to 2028 Timeframe [170-Pages] | Confirmed by Research Dive
29 mars 2022 09h01 HE
|
Research Dive
New York, USA, March 29, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global urinalysis market is anticipated to gather a revenue of $4,776.9 million by 2028 and...
Global Liver Institute Leads Second Annual Rare Liver Diseases Month
01 févr. 2022 10h41 HE
|
Global Liver Institute
Washington, DC, USA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI), a patient-led liver health nonprofit operating globally, is proud to announce today the launch of its second...